Publication Search

Search for publications by

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?


We have recently been the first to demonstrate that interleukin (IL)-27 protects against the emergence and progression of autochthonous tumors. Accumulating evidence suggests that IL-27 might be uniquely well positioned to amplify beneficial TH1 anticancer immune responses while suppressing the unwanted accumulation of regulatory T cells.

Type Journal
ISBN 2162-4011 (Print)
Authors Swarbrick, A.; Junankar, S. R.; Batten, M.;
Garvan Authors Dr Alex Swarbrick , Dr Marcel Batten
Publisher Name Oncoimmunology
Published Date 2013-08-01 00:00:00
Published Volume 2
Published Issue 8
Published Pages e25409
Status Published In-print
OpenAccess Link